KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Other Non-Current Liabilities data on record, last reported at $1.2 billion in Q2 2025.

  • For Q2 2025, Other Non-Current Liabilities changed N/A year-over-year to $1.2 billion; the TTM value through Jun 2025 reached $1.2 billion, changed N/A, while the annual FY2024 figure was $1.0 billion, 15.6% up from the prior year.
  • Other Non-Current Liabilities reached $1.2 billion in Q2 2025 per VRTX's latest filing, up from $1.0 billion in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $1.2 billion in Q2 2025 and bottomed at $127.2 million in Q3 2022.
  • Average Other Non-Current Liabilities over 5 years is $521.2 million, with a median of $437.2 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 56.01% in 2021, then surged 484.98% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $186.5 million in 2021, then surged by 267.72% to $685.8 million in 2022, then grew by 27.98% to $877.7 million in 2023, then grew by 15.6% to $1.0 billion in 2024, then increased by 17.83% to $1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $1.2 billion in Q2 2025, $1.0 billion in Q4 2024, and $853.6 million in Q1 2024.